BioSpace News Archive

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, reported that Maxine Gowen, Ph.D., has been appointed chairwoman of the board of directors for the company, effective August 31.

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, announced that Chief Executive Officer Michael Parini is scheduled to present at the following virtual investor conferences:

Centene announced two key appointments, further aligning our organization structure and operating model with our strategic priorities and accelerating impact to the business and value creation.

CollPlant announced that Mr. Yehiel Tal, Chief Executive Officer of CollPlant, will provide an overview of the company at the H.C. Wainwright 23rd Annual Global Investment Conference which will be held virtually on September 13-15, 2021.

Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, announced a partnership to accelerate the research and development of Tantu’s therapeutic genes.

Elevation Oncology, Inc., a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced that Shawn M. Leland, PharmD, Rph, Founder and Chief Executive Officer of Elevation Oncology, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference.

REGENXBIO Inc. announced the appointment of Jean Bennett, M.D., Ph.D., and George Migausky to its Board of Directors, effective September 3, 2021.